StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Nomura India Research

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byNomura India ResearchHorizon: 1 year7 Sept 2026via Zee Business (Live)

Entry₹1,880Inferred
Target₹2,150
Total upside +14.36%
Stop lossNot given
CMP₹1,838.22d ago
Active-2.22%+16.96%upside left 11 mo left
Follow Nomura India Research for new calls(100% target hit, 24 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 2 other Long-term calls on LALPATHLABSee 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:50 pm IST
18 supporting4 neutral0 opposing
Supports the BUY call (18)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·23 Oct · 2d ago

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·12 Oct · 2w ago

Dr. Lal PathLabs Ltd announces the completion of its acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, through its wholly-owned subsidiary DLPL Dubai. Sunshine Healthcare Limited is n

BSE · Company Update·26 Sept · 4w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·19 Aug · 2mo ago

Neutral / worth noting (4)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 9 days

(opens in new tab)

Dr. Lal PathLabs' subsidiary, PathLabs Unifiers Private Limited, has acquired the remaining 30% stake in Centrapath Labs Private Limited, making it a wholly owned subsidiary.

BSE · Company Update·13 Oct · 2w ago

(opens in new tab)

Dr. Lal PathLabs invested up to INR 30.3 crores in its wholly owned subsidiary, PathLabs Unifiers Private Limited, to fund the acquisition of the remaining 30% stake in CentraPath Labs Private Limited

BSE · Company Update·12 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Nomura India Research

Every call and its outcome